These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Kit Mutations: New Insights and Diagnostic Value. Falchi L; Verstovsek S Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460 [TBL] [Abstract][Full Text] [Related]
8. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase. Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996 [TBL] [Abstract][Full Text] [Related]
9. The new tool " Shomali W; Gotlib J Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):127-136. PubMed ID: 30504301 [TBL] [Abstract][Full Text] [Related]
10. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738 [TBL] [Abstract][Full Text] [Related]
11. Response and progression on midostaurin in advanced systemic mastocytosis: Jawhar M; Schwaab J; Naumann N; Horny HP; Sotlar K; Haferlach T; Metzgeroth G; Fabarius A; Valent P; Hofmann WK; Cross NCP; Meggendorfer M; Reiter A Blood; 2017 Jul; 130(2):137-145. PubMed ID: 28424161 [TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis. Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112 [TBL] [Abstract][Full Text] [Related]
13. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms. Gotlib J Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):34-46. PubMed ID: 36485158 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. DeAngelo DJ; Radia DH; George TI; Robinson WA; Quiery AT; Drummond MW; Bose P; Hexner EO; Winton EF; Horny HP; Tugnait M; Schmidt-Kittler O; Evans EK; Lin HM; Mar BG; Verstovsek S; Deininger MW; Gotlib J Nat Med; 2021 Dec; 27(12):2183-2191. PubMed ID: 34873347 [TBL] [Abstract][Full Text] [Related]
16. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392 [TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis. Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453 [TBL] [Abstract][Full Text] [Related]
18. Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee. McLornan DP; Czerw T; Damaj G; Ethell M; Gurnari C; Hernández-Boluda JC; Polverelli N; Schwaab J; Sockel K; Raffaella G; Onida F; Sánchez-Ortega I; Battipaglia G; Elena C; Gotlib J; Reiter A; Rossignol J; Ustun C; Valent P; Yakoub-Agha I; Radia DH Leukemia; 2024 Apr; 38(4):699-711. PubMed ID: 38472477 [TBL] [Abstract][Full Text] [Related]
19. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Pardanani A Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Gotlib J; Reiter A; Radia DH; Deininger MW; George TI; Panse J; Vannucchi AM; Platzbecker U; Alvarez-Twose I; Mital A; Hermine O; Dybedal I; Hexner EO; Hicks LK; Span L; Mesa R; Bose P; Pettit KM; Heaney ML; Oh ST; Sen J; Lin HM; Mar BG; DeAngelo DJ Nat Med; 2021 Dec; 27(12):2192-2199. PubMed ID: 34873345 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]